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take into account the clustering of pregnancies or 
other confounding, and further data are needed.
Nejat and Buyuk suggest that advanced pater-
nal age may underlie the association between 
ICSI and birth defects, citing Green et al.3 as 
support. However, Green et al. observed that the 
association between paternal age and birth de-
fects was nonlinear and plateaued after 30 years 
of age. Other researchers have found a U-shaped 
relationship.4,5 We have data on paternal age 
only for couples who used assisted reproductive 
technology, in whom the median paternal age at 
childbirth for recipients of IVF was 35 years, as 
compared with 36 years for ICSI. The median 
paternal age at childbirth in the Australian popu-
lation as a whole is approximately 34 years.5 
Hence, we believe that the differences in the risk 
of birth defects between IVF and ICSI are unlikely 
to be explained by variation in paternal age. In-
formation on the cause of infertility is available 
in our database, and we agree this would be of 
interest to assess in subsequent analyses.
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Anti-CD20 Antibody Therapy for B-Cell Lymphomas
To the Editor: Maloney (May 24 issue)1 enumer-
ates several mechanisms through which type I 
CD20 monoclonal antibodies such as rituximab 
and ofatumumab may target and promote the 
killing of normal and malignant B cells. One 
mechanism discussed is direct cell killing through 
the induction of apoptosis or the inhibition of 
growth and proliferation. However, an increas-
ing number of studies, including in vitro studies 
and mouse models,2-4 has presented convincing 
evidence that these antibodies do not promote 
direct B-cell killing but instead require the par-
ticipation of the body’s immune effector func-
tions. These functions (two are cited by Maloney) 
include effector-cell–mediated cytotoxicity, com-
plement-mediated killing, and phagocytosis. The 
identification of operative mechanisms is impor-
tant, because in the presence of high tumor-cell 
burdens these mechanisms will be exhausted, as 
has been shown in several clinical reports.5,6 
This complication can substantially compromise 
treatment efficacy, and the problem cannot be 
solved by adhering to current treatment guide-
lines, which involve the use of high doses of anti-
bodies. In fact, this approach is contraindicated, 
because high doses of antibodies promote the 
loss of CD20 in chronic lymphocytic leukemia, 
thus exacerbating the clinical problem and fur-
ther reducing the potential efficacy of the anti-
bodies.5,6
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To the Editor: Maloney recently reviewed the 
status of B-lymphocyte–depleting therapy with 
the chimeric antibody rituximab in non-Hodgkin 
lymphomas. As stated, the occurrence of “rituxi-
mab resistance” in some patients remains unex-
plained.
In a study of patients with Graves’ disease 
treated with rituximab without additional immu-
nosuppression,1 serum sickness–like reactions 
occurred on day 11 in 2 of 10 patients.2 Circulat-
ing levels of immune complexes containing IgM, 
IgG, and complement component 3 (C3) were 
found concurrently.2 In a similar study of 8 pa-
tients with primary Sjögren’s syndrome, serum 
sickness–like reactions developed in 3 patients 
on days 12 through 14.3 One patient had incom-
plete depletion of circulating B lymphocytes. A 
possible explanation for these findings is that 
rituximab forms complement-activating immune 
complexes with naturally occurring heterophilic 
IgM antibodies4 that recognize either the xeno-
genic part of rituximab or the Fc component (as 
alloantibodies or rheumatoid factors), thereby 
facilitating its clearance. This mechanism may 
also apply to patients with lymphoma and may 
explain at least some cases of rituximab resis-
tance. It would be useful to examine whether an 
association exists between rituximab resistance 
and the presence of rituximab-reactive hetero-
philic antibodies.
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To the Editor: In the article on rituximab ther-
apy for B-cell lymphomas, the section on hepati-
tis B virus (HBV) needs to be clarified and the 
expression “carriers of the virus” should be clear-
ly defined. According to recently published guide-
lines from the European Association for the Study 
of the Liver,1 patients with hepatitis B surface 
antigen (HBsAg)–positive disease should receive 
preemptive administration of nucleotide analogues 
during immunosuppressive therapy and should 
continue to receive these analogues for 12 months 
after the cessation of the immunosuppressive 
therapy; patients with HBsAg-negative and anti–
hepatitis B core antigen (HBcAg)–positive dis-
ease with detectable levels of HBV-DNA should 
receive the same treatment, although the evi-
dence available in support of the latter is limited. 
In patients with anti–HBcAg-positive disease with 
undetectable HBV viremia, close monitoring (with 
tests of liver function and levels of HBV DNA) is 
suggested; if monitoring is not feasible, preemp-
tive treatment is advised by some experts.2 He-
patic damage from HBV reactivation caused by 
immunosuppression or from cytotoxic T-cell re-
bound after the withdrawal of immunosuppres-
sants can be severe, and fulminant hepatitis has 
been described. It should be noted that antiviral 
therapy is usually not successful if started after 
levels of alanine aminotransferases become ele-
vated.3 Given the efficacy of preemptive antiviral 
therapy, patients infected with HBV should be 
carefully evaluated before being treated with bio-
logic response modifiers.
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The Author Replies: Nearly 15 years after the 
initial approval of rituximab, we still do not un-
derstand the precise roles played by complement 
and antibody-dependent cell-mediated cytotoxic-
ity in the actual clinical response of tumor cells 
in patients with lymphoma or chronic lympho-
cytic leukemia. Nor do we understand the effects 
of factors such as growth inhibition, apoptosis, 
and synergy or the result when rituximab is used 
in combination with other cytotoxic or novel 
agents. Many factors influence the sensitivity of 
tumor cells to antibody-mediated killing, and the 
responses of lymphomas and chronic lympho-
cytic leukemia probably differ. Disease location 
(e.g., lymph nodes, extranodal masses, spleen, 
blood, and bone marrow) influences antibody ac-
cess to the tumor cells and to host effector mech-
anisms, and each tissue type probably sends sur-
vival signals to tumor cells.
I certainly appreciate the expertise of Taylor 
et al. on the human complement system, and 
complement appears to be involved in the mech-
anism of action of type I anti-CD20 antibodies. 
However, I believe that complement is only a 
part of a very complicated picture. Clinical trials 
of next-generation antibodies such as ofatumu-
mab and obinutuzumab have produced results 
that are similar to the results of lymphoma trials 
in which rituximab is used. (Ofatumumab aug-
ments complement activation, and obinutuzumab 
is a type II anti-CD20 antibody that has little ef-
fect on complement activation and greater inter-
action with FcγRIIIa receptors and antibody-
dependent cell-mediated cytotoxicity.) Both agents 
appear to be active in chronic lymphocytic leuke-
mia, which suggests that multiple mechanisms 
are active.1,2 It is hoped that clinical trials with 
these next-generation anti-CD20 antibodies will 
further elucidate the dominant mechanisms of 
action.
In a similar fashion, the causes of antibody 
resistance are multifactorial, ranging from anti-
gen loss to the exhaustion of effector mecha-
nisms. Greater attention to antibody pharmaco-
kinetics, target saturation and modulation, and 
effector mechanisms is warranted to understand 
the mechanisms of both action and resistance. 
The generation of immune responses against 
rituximab is an additional mechanism of resis-
tance, although it is only infrequently observed 
in the treatment of patients with B-cell cancers. 
In contrast, patients with autoimmune or rheu-
matologic disease who are treated with rituxi-
mab have a higher risk of immune responses 
that may limit treatment, as pointed out by El 
Fassi et al. It is hoped that the replacement of 
chimeric antibodies with humanized or human 
antibodies will diminish this complication in the 
future.
I appreciate the additional information provid-
ed by Calcagno et al. regarding recent recommen-
dations on the care of patients with hepatitis B 
who are being treated with immunosuppressive 
agents, including anti-CD20 antibodies. Space 
limitations have kept me from fully addressing 
this and many other issues in the broad topic of 
anti-CD20 antibody therapy for lymphoma.
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